AU2002352498A1 - Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers - Google Patents

Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Info

Publication number
AU2002352498A1
AU2002352498A1 AU2002352498A AU2002352498A AU2002352498A1 AU 2002352498 A1 AU2002352498 A1 AU 2002352498A1 AU 2002352498 A AU2002352498 A AU 2002352498A AU 2002352498 A AU2002352498 A AU 2002352498A AU 2002352498 A1 AU2002352498 A1 AU 2002352498A1
Authority
AU
Australia
Prior art keywords
ikb
cancers
inhibitors
treatment
multiple myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002352498A
Other languages
English (en)
Inventor
Julian Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2002352498A1 publication Critical patent/AU2002352498A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002352498A 2001-11-07 2002-11-06 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers Abandoned AU2002352498A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34491101P 2001-11-07 2001-11-07
US60/344,911 2001-11-07
PCT/US2002/035645 WO2003039545A2 (en) 2001-11-07 2002-11-06 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Publications (1)

Publication Number Publication Date
AU2002352498A1 true AU2002352498A1 (en) 2003-05-19

Family

ID=23352621

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002352498A Abandoned AU2002352498A1 (en) 2001-11-07 2002-11-06 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers

Country Status (6)

Country Link
US (1) US9248124B2 (enExample)
EP (1) EP1443927B1 (enExample)
JP (2) JP4599501B2 (enExample)
AU (1) AU2002352498A1 (enExample)
DE (1) DE60217532T8 (enExample)
WO (1) WO2003039545A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60217532T8 (de) * 2001-11-07 2008-02-07 Millennium Pharmaceuticals, Inc., Cambridge Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
JP2006522824A (ja) * 2003-04-09 2006-10-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患を処置するために有用なβ−カルボリン
DE10326821A1 (de) * 2003-06-11 2005-01-05 Medical Enzymes Ag Pharmazeutische Kombinationspräparate zur Krebstherapie
JP2007532582A (ja) 2004-04-09 2007-11-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置に有用なβ−カルボリン
CN100443178C (zh) 2006-03-10 2008-12-17 中国石油天然气股份有限公司 一种乙烯低聚的催化剂组合物及其应用
US8426355B2 (en) 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
EP2185153A4 (en) * 2007-08-03 2012-02-29 Univ California INTRACELLULAR UROKINASE PLASMINOGEN ACTIVATOR INHIBITORS AND METHODS OF USE
US20090137579A1 (en) * 2007-10-23 2009-05-28 Millennium Pharmaceuticals, Inc. Mesylate salt of an IKK inhibitor
US20090131422A1 (en) * 2007-10-23 2009-05-21 Millennium Pharmaceuticals, Inc. Salts of an IKK inhibitor
TW201512199A (zh) * 2008-06-11 2015-04-01 Genentech Inc 二氮雜咔唑及使用方法
EP2161271A1 (en) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
WO2010099445A2 (en) * 2009-02-26 2010-09-02 Board Of Trustees Of Michigan State University Non-covalent inhibition of the 26s proteasome and uses thereof
FR2953837B1 (fr) * 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2303627B (en) * 1995-07-26 1997-07-09 Arab Pharmaceutical Mfg Co Ltd Anti-tumour platinum-harmine complex
CA2301979A1 (en) * 1997-09-10 1999-03-18 Uab Research Foundation Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
JPH11180873A (ja) * 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
DE19807993A1 (de) 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
CA2402549A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
DE60217532T8 (de) * 2001-11-07 2008-02-07 Millennium Pharmaceuticals, Inc., Cambridge Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas

Also Published As

Publication number Publication date
JP2005529842A (ja) 2005-10-06
WO2003039545A2 (en) 2003-05-15
EP1443927A2 (en) 2004-08-11
HK1069311A1 (en) 2005-05-20
WO2003039545A3 (en) 2003-10-30
DE60217532T2 (de) 2007-10-31
JP4599501B2 (ja) 2010-12-15
US20050049265A1 (en) 2005-03-03
EP1443927B1 (en) 2007-01-10
DE60217532T8 (de) 2008-02-07
DE60217532D1 (de) 2007-02-22
JP2010031061A (ja) 2010-02-12
US9248124B2 (en) 2016-02-02

Similar Documents

Publication Publication Date Title
AU2002352498A1 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
AU2003280188A1 (en) Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
AU2003243318A1 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2003230750A1 (en) Compositions and methods for treating cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AU2003284242A1 (en) Methods and compositions for use in treating cancer
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
AU2002219782A1 (en) Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2003291356A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
AU2003259735A1 (en) Small-mer compositions and methods of use
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003299441A1 (en) Nf-hev compositions and methods of use
AU2003247784A1 (en) Compositions and methods for treatment and detection of multiple cancers
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2003215244A1 (en) Complexes and methods of using same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase